> ## Content Index
> Fetch the complete content index at: https://www.elenapintea.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# ICH S8 and S6 in plain language: immunotoxicity for small molecules vs biologics
- URL: https://www.elenapintea.com/ich-s8-and-s6-in-plain-language-immunotoxicity-for-small-molecules-vs-biologics/
- Published: 2026-10-12T20:16:05.000Z
- Updated: 2026-11-19T16:24:26.000Z
- Description: Two ICH guidelines shape how drug developers assess effects on the immune system before human use: ICH S8 for immunotoxicity of pharmaceuticals, and ICH S6(R1) for biotechnology-derived products. They answer the same broad question, but in different ways.
- Author: Elena Pintea
- Tags: Immunosafety

Two ICH guidelines shape how drug developers assess effects on the immune system before human use: ICH S8 for immunotoxicity of pharmaceuticals, and ICH S6(R1) for biotechnology-derived products. They answer the same broad question, but in different ways.

I studied both during the Immunosafety and Regulatory Aspects modules of my MSc in Drug Sciences at the University of Basel. This article explains what each one asks for and why the approaches differ.

### What "immunotoxicity" means in regulatory terms

In ICH S8, immunotoxicity mainly means *unintended* immunosuppression or immune enhancement (International Council for Harmonisation \[ICH\], 2005). It covers effects such as a reduced ability to fight infections or an inflammatory response the drug was never meant to cause.

S8 explicitly excludes allergic reactions and drug-specific autoimmunity. These remain important clinical risks, but there are no well-validated nonclinical models to predict them reliably (ICH, 2005).

### ICH S8: a weight-of-evidence approach

S8 does not require a fixed immunotoxicity test for every new drug. Instead, it asks developers to look first at data they already have from standard toxicity studies.

The signals reviewers look for include:

- changes in white blood cell counts and differential counts;
- altered weights or histopathology of the thymus, spleen and lymph nodes;
- changes in serum globulins;
- an increased rate of infections or tumours in animals (ICH, 2005).

Other factors can also trigger further investigation. These include the drug's pharmacology, an intended patient population that is already immunocompromised, structural similarity to known immunomodulators, and accumulation of the drug in immune cells.

If the weight of evidence suggests a concern, additional studies follow. The most commonly recommended is the T-cell dependent antibody response (TDAR) assay, which tests whether the immune system can still mount a normal response to a new antigen (ICH, 2005).

### ICH S6(R1): when the drug itself is a protein

Biotechnology-derived products, such as monoclonal antibodies and recombinant proteins, are handled differently. ICH S6(R1) recognises that standard small-molecule testing often does not make sense for them (ICH, 2011).

Three differences stand out:

1. **Species relevance.** A toxicity study is only meaningful in a species where the drug binds its target and is pharmacologically active. For many antibodies, that limits testing to non-human primates or requires surrogate molecules.
2. **Intended pharmacology drives the assessment.** Many biologics are *designed* to modulate the immune system. The question is less "does it affect immunity?" and more "is the effect exaggerated or longer-lasting than intended?"
3. **Immunogenicity.** Animals often develop anti-drug antibodies against human proteins. These can neutralise the drug or change its exposure, so they must be measured to interpret the toxicity results correctly (Descotes, 2009; ICH, 2011).

S6(R1) also notes that standard genotoxicity studies are usually not needed for proteins, and that carcinogenicity is assessed case by case (ICH, 2011).

### A side-by-side view

| Question             | Small molecules (ICH S8)                      | Biologics (ICH S6(R1))                                     |
| -------------------- | --------------------------------------------- | ---------------------------------------------------------- |
| Starting point       | Standard toxicity study data                  | Intended pharmacology and target biology                   |
| Test species         | Standard rodent and non-rodent                | Pharmacologically relevant species only                    |
| Typical extra study  | TDAR when weight of evidence suggests concern | Case by case, often built into general toxicity studies    |
| Anti-drug antibodies | Rarely relevant                               | Must be measured and interpreted                           |
| Main concern         | Unintended immunosuppression or enhancement   | Exaggerated pharmacology, cytokine release, immunogenicity |

### Why this distinction matters in practice

Understanding these frameworks helps when reading a product's safety profile. If a small molecule shows unexpected infections in clinical use, a reviewer can check whether the nonclinical package flagged any lymphoid organ changes. If a biologic causes infusion reactions, the questions turn to cytokine release and immunogenicity.

The same logic matters for pharmacovigilance. Risk management plans often list important potential risks such as serious infections, malignancy or hypersensitivity (ICH, 2004). Many of these trace back to what was, or could not be, assessed under S8 and S6.

### The connection to my research

My thesis studied how pharmacological agents change the inflammatory and metabolic behaviour of LPS-stimulated macrophages, using ELISA cytokine quantification and FIA-MS metabolomics. That kind of mechanistic in vitro work sits alongside the regulatory studies described here.

It cannot replace them, but it can help explain a finding. When a standard toxicity study shows altered immune parameters, mechanistic data helps decide whether the effect is likely to translate to patients.

### Why employers should care

In drug development, regulatory affairs and safety, people who understand both the guideline text and the biology behind it are valuable. They can read a nonclinical summary critically, anticipate questions from authorities and connect early findings to later clinical risks.

My combination of pharmacy practice, immunopharmacology research and regulatory training is aimed precisely at that bridge.

### Key takeaways

- ICH S8 uses a weight-of-evidence approach, with TDAR as the main follow-up study.
- ICH S6(R1) adapts testing to biologics: relevant species, intended pharmacology and immunogenicity.
- Both frameworks shape the immune-related risks that later appear in risk management plans.

### References

Descotes, J. (2009). Immunotoxicity of monoclonal antibodies. *mAbs, 1*(2), 104–111.

International Council for Harmonisation. (2004). *Pharmacovigilance planning E2E*. https://www.ich.org

International Council for Harmonisation. (2005). *Immunotoxicity studies for human pharmaceuticals S8*. https://www.ich.org

International Council for Harmonisation. (2011). *Preclinical safety evaluation of biotechnology-derived pharmaceuticals S6(R1)*. https://www.ich.org